lenalidomide has been researched along with Neoplasms, Plasma Cell in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 4 (80.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hountras, P; Lane, T | 1 |
| Acosta-Rivera, M; Agarwal, A; Anz, B; Bahlis, NJ; Bar, M; Berdeja, J; Chung, W; Fonseca, G; Ganguly, S; Lee, K; Matous, J; Mouro, J; Quick, D; Reece, D; Samaras, C; Schiller, GJ; Sebag, M; Seet, CS; Siegel, DS; Song, K | 1 |
| Cascavilla, N; Curci, P; Di Renzo, N; Falcone, AP; Germano, C; Guarini, A; Mazza, P; Mele, A; Mele, G; Melillo, L; Musto, P; Palazzo, G; Palumbo, G; Pastore, D; Pavone, V; Reddiconto, G; Rossini, B; Specchia, G; Tarantini, G | 1 |
| Imataki, O; Ishino, R; Kadowaki, N; Oku, M; Sugimoto, N; Todo, T; Uchida, S | 1 |
| Cortelezzi, A; Fattizzo, B; Ferla, V; Fracchiolla, NS; Freyrie, A; Iurlo, A; Reda, G | 1 |
1 trial(s) available for lenalidomide and Neoplasms, Plasma Cell
| Article | Year |
|---|---|
Pomalidomide, dexamethasone, and daratumumab immediately after lenalidomide-based treatment in patients with multiple myeloma: updated efficacy, safety, and health-related quality of life results from the phase 2 MM-014 trial.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Neoplasms, Plasma Cell; Quality of Life; Thalidomide | 2022 |
4 other study(ies) available for lenalidomide and Neoplasms, Plasma Cell
| Article | Year |
|---|---|
A 65-Year-Old Man With Weight Loss, Peripheral Neuropathy, and Lower Extremity Swelling.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Edema; Exercise Tolerance; Humans; Hypertension, Pulmonary; Lenalidomide; Male; Neoplasms, Plasma Cell; Peripheral Nervous System Diseases; Phosphodiesterase 5 Inhibitors; POEMS Syndrome; Positron Emission Tomography Computed Tomography; Stem Cell Transplantation; Syncope; Tadalafil; Weight Loss | 2022 |
Daratumumab plus bortezomib or daratumumab plus lenalidomide as salvage therapy for patients with myeloma: initial follow-up of an Italian multicentre retrospective clinical experience by 'Rete Ematologica Pugliese'.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Follow-Up Studies; Humans; Lenalidomide; Multiple Myeloma; Neoplasms, Plasma Cell; Retrospective Studies; Salvage Therapy | 2022 |
Oncolytic herpes simplex virus type 1 (HSV-1) in combination with lenalidomide for plasma cell neoplasms.
Topics: Aged; Animals; Cell Line, Tumor; Female; Herpesvirus 1, Human; Humans; Immunologic Factors; Interferon-alpha; Lenalidomide; Male; Mice, SCID; Neoplasms, Plasma Cell; Oncolytic Virotherapy; Oncolytic Viruses | 2021 |
Concomitant Occurrence of Blastic Plasmacytoid Dendritic Cell Neoplasm and Acute Myeloid Leukaemia after Lenalidomide Treatment for.
Topics: Chromosome Deletion; Dendritic Cells; Humans; Immunologic Factors; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Neoplasms, Plasma Cell; Thalidomide; Treatment Outcome | 2017 |